FONDATION-IPSEN
26.11.2015 15:01:22 CET | Business Wire | Press release
The 20th annual Longevity Prize of the Fondation IPSEN has been awarded to Steven N. Austad (University of Alabama at Birmingham, USA ), in recognition of his outstanding leadership in the domain of the comparative biology of aging (especially the study of species resisting to aging), by an international jury led by Thomas Kirkwood (Newcastle University, Newcastle, UK ). He received the €20,000 prize on November 21st , 2015 at the Gerontology Society of America (GSA) in Orlando, USA where he presented an outstanding lecture.
“Evolution is smarter than you are.” That quote from biochemist Leslie Orgel forms the basis for looking to nature for creative ways to slow the damaging processes of aging. Ironically, the laboratory animals scientists generally use to try to understand aging processes – and learn how to retard them – are demonstrably unsuccessful at combating these degenerative processes. It doesn’t take long to determine whether the researchers have succeeded in lengthening their health- and lifespan. On the other hand, methods for making an animal that normally lives 2 years survive to age 4, may not be relevant for an animal – humans – that already lives 80 years or more. A complementary approach is to scour nature for animals that nature has already given the tools to combat aging successfully and to try to discover what those tools are and how they work. Animals that are more successful than humans at resisting aging processes are abundant on earth. The research of Steven N. Austad has employed a number of such species over the years.
Dr. Austad is Distinguished Professor and Chair of the Department of Biology at the University of Alabama at Birmingham and also Scientific Director of the American Federation for Aging Research. After receiving his PhD degree from Purdue University, he accepted his first faculty position as Assistant Professor at Harvard University in 1986. He subsequently moved to the University of Idaho where he became full professor in 1997. In 2004, he joined the Barshop Institute for Longevity & Aging Studies at the University of Texas Health Science Center San Antonio in San Antonio, Texas before moving to his current position in 2014. His research encompasses many aspects of the biology of aging from the molecular to the population level. His research specialty is the identification and study of nontraditional species – particularly exceptionally long-lived species – for insight into processes of slow aging. Dr. Austad’s research has won multiple previous awards, including the Geron Corporation-Samuel Goldstein Distinguished Publication Award, the Nathan A. Shock Award, the Robert W. Kleemeier Award, the Purdue Outstanding Alumnus Award, and the Irving S. Wright Award of Distinction.
Previous laureates of the Longevity Prize
Founded in 1996,
the Longevity Prize of the Fondation IPSEN has been awarded to renowned
specialists: Caleb E. Finch (Los Angeles, 1996)
, Vaino Kannisto (Lisboa,
1997),
Roy L. Walford (Los Angeles, 1998),
John Morley (St
Louis,1999),
Paul & Margret Baltes (Berlin, 2000),
Justin
Congdon (Aiken, 2001),
George Martin (Seattle, 2002),
James
Vaupel (Rostock, 2003),
Linda Partridge (London, 2004),
Sir
Michael Marmot (London, 2005),
Cynthia Kenyon (San Francisco,
2006),
David Barker (Southampton, 2007),
Gerald McLearn
(University Park, 2008
), Jacques Vallin (Paris, 2009),
Judith
Campisi (Novato, 2010), Tom Kirkwood (Newcastle, 2011),
Linda
Fried (New York, 2012),
Gary Ruvkun (Boston, 2013),
Luigi
Ferrucci (Baltimore, 2014).
The jury members of the Longevity Prize
Thomas Kirkwood (Newcastle
University, Newcastle, UK
), President
Judith Campisi (Buck
Institute for Research on Ageing, Novato, USA
), Eileen Crimmins (University
of Southern California, Los Angeles, USA
), Caleb Finch (University
of Southern California, Los Angeles, USA
), Bernard Jeune (Odense
Universitet, Odense, Denmark
), George Martin (University of
Washington, Seattle, USA
), Jean-Marie Robine (INSERM, Démographie
et Santé, Montpellier, France
), Bruno Vellas (Hôpital Purpan,
Toulouse, France
) and a Fondation IPSEN representative.
About the Fondation IPSEN
Established in 1983 under the
aegis of the Fondation de France, the mission of the Fondation IPSEN is
to contribute to the development and dissemination of scientific
knowledge. The long-standing action of the Fondation IPSEN aims at
fostering the interaction between researchers and clinical
practitioners, which is essential due to the extreme specialization of
these professions. The ambition of the Fondation IPSEN is to initiate a
reflection about the major scientific issues of the forthcoming years.
It has developed an important international network of scientific
experts who meet regularly at meetings known as Colloques Médecine et
Recherche
, dedicated to six main themes: Alzheimer's disease,
neurosciences, longevity, endocrinology, the vascular system and cancer
science. Moreover the Fondation IPSEN has started since 2007 several
meetings in partnership with the Salk Institute, the Karolinska
Institutet, the Massachusetts General Hospital, the Days of Molecular
Medicine Global Foundation as well as with the science journals Nature
,
Cell
and Science
. The Fondation IPSEN produced several
hundred publications; more than 250 scientists and biomedical
researchers have been awarded prizes and research grants.
www.fondation-ipsen.org
View source version on businesswire.com: http://www.businesswire.com/news/home/20151126005262/en/
Contact:
Image Sept
Isabelle de Segonzac, Tel: +33 (0)1 53 70 74 70
Email:
isegonzac@image7.fr
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ushio Industry & Entertainment Appoints Takuya Matsumoto as President & CEO and Outlines Strategic Direction for the Next Phase20.4.2026 12:32:00 CEST | Press release
Ushio Industry & Entertainment (Ushio INE GmbH) announces the appointment of Takuya Matsumoto as President and Chief Executive Officer, marking a key milestone in the evolution of the business and its integration within the Ushio Group. With more than 20 years of experience across sales, new business development, and global operations, Takuya Matsumoto brings deep industry expertise and a strong leadership track record within Ushio. Most recently, he served as General Manager of the Global Business Unit, where he played a pivotal role in advancing global growth initiatives. A Clear Vision: A strong heritage with a forward-looking vision focused on innovation, operational excellence, and customer value Under Takuya Matsumoto’s leadership, Ushio INE will continue to build on its strong legacy while advancing its mission to deliver high-performance, high-quality lighting solutions across industrial and entertainment markets worldwide. “Our mission is to continuously deliver essential ligh
Compass Pathways to Participate in Needham Virtual Psychedelics Forum on April 27, 202620.4.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that CEO Kabir Nath will participate in a panel entitled “Clinical Risk, Regulatory Reality and the Path to Scale” at the Needham Virtual Psychedelics Forum on April 27, 2026, at 11am-12pm ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable response
PPG invests in testing line for radiation-curable coatings at Marly, France20.4.2026 11:00:00 CEST | Press release
Installation helps accelerate development cycles, reduce number of customer trials PPG (NYSE: PPG) today announced the installation of an advanced testing line for radiation-curable coatings at its R&D Center of Excellence in Marly, France. The line can test multiple curing technologies, including infrared (IR), ultraviolet (LED, excimer and arc lamps), and electron beam (EB). This investment allows the company to accurately replicate customer production conditions, helping accelerate development cycles and reduce the number of customer trials. Unlike conventional thermal curing, radiation curing requires less energy because it operates at or near ambient temperature. This reduction in energy demand can significantly lower carbon emissions by 65%*, with further gains possible when powered by renewable energy sources. In addition, UV- and EB-curable systems typically use 100% solids formulations with no solvents, reducing or eliminating volatile organic compound emissions. Beyond sustai
IQOSand Devialet Introduce “Soundsorial Design” Collaboration20.4.2026 10:00:00 CEST | Press release
Exhibition and capsule collection drop at Milan Design Week 2026 Philip Morris International (NYSE: PM) today announced a collaboration between IQOS – the number 1 tobacco heating system1, and Devialet – the French acoustic engineering company, launching “Soundsorial Design” at Milan Design Week 2026. The immersive exhibition is an ethereal landscape of water and light, where sound, movement, and voice become visible across an ever‑changing immersive canvas. A space to push experiential boundaries, where visitors are invited to explore their own frequency as sound transforms into sight.The collaboration celebrates self-expression while connecting a community of over 35 million IQOS users who moved away from cigarettes. Devialet’s mission to give sound its rightful place in our lives, achieved through acoustic breakthroughs, meets IQOS’s bold spirit of being forever curious – the force that pushes the brand to continuously innovate and explore new technologies for a better future. Two p
Europe’s Technology Services Market Accelerates in Q1 on Higher Demand for AI: ISG Index™20.4.2026 10:00:00 CEST | Press release
Combined market up 30%, to record US $12.2 billion, fueled by strong AI-driven IaaS growth Demand for technology services in Europe continued to accelerate in the first quarter, driven by strong demand for the cloud-based infrastructure services needed to power AI, the latest state-of-the-industry report from Information Services Group (ISG) (Nasdaq: III), a leading global technology research and advisory firm, shows. The EMEA ISG Index™, which measures commercial outsourcing contracts with annual contract value (ACV) of US $5 million or more, shows ACV for the combined market (both managed services and cloud-based as-a-service) climbed 30 percent in the first quarter, to a record US $12.2 billion. Sequentially, the market was up 12 percent from its previous high in the fourth quarter. Over the last seven quarters, EMEA’s combined market has risen by double-digits in six of them, averaging 22 percent year-on-year growth in that span. “Europe has clearly turned the corner, as the region
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
